



Information on total number of voting rights and shares composing the share capital as at September 30, 2019

Paris, October 1st, 2019 – 6.00PM CET - Pixium Vision (FR0011950641 - PIX), a bioelectronic company developing innovative bionic vision systems to allow patients who have lost their sight to lead more independent lives, announces the evolution of its share capital. The number of voting rights and shares composing its share capital as at September 30, 2019 is as follow:

Total voting rights	Total number of shares composing capital
Total real voting rights ⁽¹⁾ : 22,534,266	22,606,060 ⁽³⁾
Total theoretical voting rights ⁽²⁾ : 22,606,060	

(1): The actual (or net) voting rights correspond to the total number of voting rights exercisable at General Meetings. They are calculated based on the total number of voting rights attached to the total number of shares, less any shares without voting rights (treasury shares, etc.).

(2): Theoretical (or gross) voting rights include all voting rights attached to the shares (including those without voting rights).

(3): Including 665,000 new shares in accordance with the contract of Equity Line financing concluded with Kepler Cheuvreux on December 21, 2018

Contacts

Pixium Vision

Didier Laurens

Chief Financial Officer

investors@pixium-vision.com

+33 1 76 21 47 68

Media relations

LifeSci Advisors

Sophie Baumont

sophie@lifesciadvisors.com

+33 6 27 74 74 49

Investors relation

LifeSci Advisors

Chris Maggos

chris@lifesciadvisors.com

+41 79 367 62 54

For more information, please visit: <http://www.pixium-vision.com/fr>

And follow us on : [@PixiumVision](https://twitter.com/PixiumVision); www.facebook.com/pixiumvision

www.linkedin.com/company/pixium-vision



Pixium Vision is listed on Euronext Paris (Compartment C).

Pixium Vision shares are eligible for the French tax incentivized PEA-PME and FCPI investment vehicles.

Pixium Vision is included in the Euronext CAC All Shares index
Euronext ticker: PIX - ISIN: FR0011950641 – Reuters: PIX.PA –